On September 18, HoneyNaps USA, a provider of AI-based sleep medicine solutions, declared that it had successfully wrapped up its participation at the 18th World Sleep Congress (World Sleep 2025), which took place at the Suntec Convention & Exhibition Centre in Singapore from September 5–10. HoneyNaps USA demonstrated its main technology to international medical professionals during this Congress, and it saw real progress in growing international alliances.
Experts and businesses from all around the world in sleep medicine come together at the World Sleep Congress. Two iterations of HoneyNaps USA’s FDA-approved AI-based Polysomnography (PSG) automatic scoring solution—the installable SOMNUM Pro and the web-based SOMNUM Cloud—attracted a lot of interest.
Hospital computers can have SOMNUM Pro installed as a stand-alone program. In order to provide polysomnography reports, it automatically rates PSG data using AI. It also offers a scoring window that graphically displays the AI’s scoring for each event.
SOMNUM Cloud is an online version that doesn’t require any software to be installed. The AI automatically analyzes the data and delivers a printable polysomnography report when users upload EDF files that have been extracted from PSG equipment.c has good scores for medical data privacy because it works on a secure server that complies with ISO/IEC 27001 certification and HIPAA rules, in addition to offering raw data score results.
Over 35 countries sent medical professionals to visit HoneyNaps USA’s booth during the congress, including industrialized markets like the UK, France, and Germany, Latin American countries like Brazil and Mexico, Asian countries like China, Japan, and Taiwan, and Middle Eastern countries like Saudi Arabia and the United Arab Emirates. The company reported a larger visitor turnout than the previous SLEEP 2025 and the Congress of the ESRS, despite the exhibition’s relatively modest scale. This indicates the growing passion in the field.
Six contracts were signed as a result of the congress’s more than 260 business inquiries. Furthermore, exclusive distributorship agreements were actively discussed in a number of nations, and follow-up talks about particular contract terms and supply patterns are currently under progress. Additionally, more than 150 trial applications from people eager to try AI Auto-scoring with SOMNUM Cloud were received. On the basis of these, HoneyNaps USA intends to develop customer service and product distribution plans tailored to each nation.
Taekyoung (Sean) Ha, PhD, President of HoneyNaps USA, stated, “We will begin by following up with the trial applicants we signed up at the exhibition, while simultaneously establishing local distributor systems and pursuing regulatory approval processes for medical devices in key target countries. As a leading company in the global commercialization of AI sleep medical technology, we aim to rapidly expand our presence in the international healthcare market through not only technological excellence but also practical service delivery and strong partnerships.”
HoneyNaps USA intends to step up its international expansion efforts in response to the comments received during the expo and the worldwide demand. The business will first concentrate on interacting with trial clients while progressively moving medical device regulatory clearance procedures forward in various nations. Additionally, it plans to set up legitimate distributor networks, especially in areas like Europe and the Middle East where there is a robust market response. Additionally, it is thinking about growing field applications through collaborative research and pilot projects with medical institutions.
Disclaimer:
The information contained in this article is for educational and informational purposes only and is not intended as a health advice. We would ask you to consult a qualified professional or medical expert to gain additional knowledge before you choose to consume any product or perform any exercise.
